Florida-headquartered Stiefel Laboratories, which says it is the world's largest independent drugmaker specializing in dermatology, says that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired, for its proposed $148.0 million acquisition of fellow USA-based Barrier Therapeutics (Marketletter June 30).
As previously announced, Stiefel and Bengal Acquisition, a direct wholly-owned subsidiary, signed a definitive merger agreement to buy Barrier through a two-step transaction - a tender offer followed by a merger of Bengal with and into Barrier. The transaction was approved by the board of directors of Barrier. Stiefel is accomplishing the acquisition of Barrier through a tender offer, which commenced on July 8 and is scheduled to expire at 12:00 midnight, New York City time, on August 4, unless, subject to the terms of the merger agreement, the tender offer is extended.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze